Different Recognition of DNA Modified by Antitumor Cisplatin and Its Clinically Ineffective trans Isomer by Tumor Suppressor Protein p53

Journal of Biological Chemistry

Volumn 276, Issue 19, 2001, Pages 16064-16069

  Kasparkova, Jana ^a   Pospisilova, Sarka ^b   Brabec, Viktor ^a  

^a INSTITUTE OF BIOPHYSICS   (Czech Republic)

^b MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG PRODUCTS; GENETIC ENGINEERING; ISOMERS; PROTEINS; TUMORS;

CISPLATIN ADDUCTS;

DNA;

CISPLATIN; DNA FRAGMENT; NUCLEAR PROTEIN; OLIGODEOXYRIBONUCLEOTIDE; PHOSPHOPROTEIN; PROTEIN P53; TRANSPLATIN; CISPLATIN DNA ADDUCT; CISPLATIN-DNA ADDUCT; RECOMBINANT PROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; COMPLEX FORMATION; CROSS LINKING; DNA ADDUCT; DNA CONFORMATION; DNA MODIFICATION; DNA SEQUENCE; GENOTOXICITY; HUMAN; MOLECULAR RECOGNITION; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN FUNCTION; STEREOCHEMISTRY; TRANS ISOMER; ANIMAL; ARMYWORM; BINDING SITE; CELL LINE; CHEMISTRY; CONSENSUS SEQUENCE; ENZYME SPECIFICITY; GENETIC TRANSFECTION; ISOMERISM; METABOLISM; NUCLEOTIDE SEQUENCE;

ANIMALS; BASE SEQUENCE; BINDING SITES; CELL LINE; CISPLATIN; CONSENSUS SEQUENCE; DNA ADDUCTS; HUMANS; ISOMERISM; OLIGODEOXYRIBONUCLEOTIDES; RECOMBINANT PROTEINS; SPODOPTERA; SUBSTRATE SPECIFICITY; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0035844151     PISSN: 00219258     EISSN: None     Source Type: Journal    
DOI: 10.1074/jbc.M101224200     Document Type: Article

References (37)

1. Wong, E., and Giandomenico, C. M. (1999) Chem. Rev. 99, 2451-2466
2. O'Dwyer, P. J., Stevenson, J. P., and Johnson, S. W. (1999) in Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug (Lippert, B., ed) pp. 31-72, Verlag Helvetica Chimica Acta, Zurich
3. Jamieson, E. R., and Lippard, S. J. (1999) Chem. Rev. 99, 2467-2498
4. Rosenberg, B. (1999) in Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug (Lippert, B., ed) pp. 3-30, Verlag Helvetica Chimica Acta, Zurich
5. Brabec, V., Kleinwächter, V., Butour, J. L., and Johnson, N. P. (1990) Biophys. Chem. 35, 129-141
6. Leng, M., Schwartz, A., and Giraud-Panis, M. J. (2000) in Platinum-Based Drugs in Cancer Therapy (Kelland, L. R., and Farrell, N. P., eds) pp. 63-85, Humana Press Inc., Totowa, NJ
7. Leng, M., Locker, D., Giraud-Panis, M. J., Schwartz, A., Intini, F. P., Natile, G., Pisano, C., Boccarelli, A., Giordano, D., and Coluccia, M. (2000) Mol. Pharmacol. 58, 1525-1535
8. Eastman, A. (1999) in Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug (Lippert, B., ed) pp. 111-134, Verlag Helvetica Chimica Acta, Zurich
9. Zamble, D. B., and Lippard, S. J. (1999) in Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug (Lippert, B., ed) pp. 73-110, Verlag Helvetica Chimica Acta, Zurich
10. Jordan, P., and Carmo-Fonseca, M. (2000) Cell. Mol. Life Sci. 57, 1229-1235
11. Burns, T. F., and El-Deiry, W. S. (1999) J. Cell. Physiol. 181, 231-239
12. Bates, S., and Vousden, K. H. (1999) Cell. Mol. Life Sci. 55, 28-37
13. Janus, F., Albrechtsen, N., Dornreiter, I., Wiesmüller, L., Grosse, F., and Deppert, W. (1999) Cell. Mol. Life Sci. 55, 12-27
14. May, P., and May, E. (1999) Oncogene 18, 7621-7636
15. Zamble, D. B., Tyler, J., and Lippard, S. J. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 6163-6168
16. O'Connor, P. M., Jackman, J., Bae, I., Myers, T. G., Fan, S., Mutoh, M., Scudiero, D. A., Monks, A., Sausville, E. A., and Weinstein, J. N. (1997) Cancer Res. 57, 4285-4300
17. El-Deiry, W. S., Kern, S. E., Pietenpol, J. A., Kinzler, K. W., and Vogelstein, B. (1992) Nat. Genet. 1, 45-49
18. Nagaich, A. K., Zhurkin, V. B., Durell, S. R., Jernigan, R. L., Appella, E., and Harrington, R. E. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 1875-1880
19. Wetzel, C. C., and Berberich, S. J. (1998) Oncology Res. 10, 151-161
20. Brabec, V., Reedijk, J., and Leng, M. (1992) Biochemistry 31, 12397-12402
21. Kasparkova, J., Farrell, N., and Brabec, V. (2000) J. Biol. Chem. 275, 15789-15798
22. Hupp, T. R., and Lane, D. P. (1995) J. Biol. Chem. 270, 18165-18174
23. Kim, S. D., Vrana, O., Kleinwächter, V., Niki, K., and Brabec, V. (1990) Anal. Lett. 23, 1505-1518
24. Lemaire, M. A., Schwartz, A., Rahmouni, A. R., and Leng, M. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 1982-1985
25. Brabec, V., and Leng, M. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 5345-5349
26. Bellon, S. F., Coleman, J. H., and Lippard, S. J. (1991) Biochemistry 30, 8026-8035
27. Kasparkova, J., and Brabec, V. (1995) Biochemistry 34, 12379-12387
28. Brabec, V., Neplechova, K., Kasparkova, J., and Farrell, N. (2000) J. Biol. Inorg. Chem. 5, 364-368
29. Vojtesek, B., Bartek, J., Midgley, C. A., and Lane, D. P. (1992) J. Immunol. Methods 151, 237-244
30. Mazur, S. J., Sakaguchi, K., Appella, E., Wang, X. W., Harris, C. C., and Bohr, V. A. (1999) J. Mol. Biol. 292, 241-249
31. Yang, D. Z., van Boom, S. S. G. E., Reedijk, J., van Boom, J. H., and Wang, A. H. J. (1995) Biochemistry 34, 12912-12920
32. Gelasco, A., and Lippard, S. J. (1998) Biochemistry 37, 9230-9239
33. Brabec, V. (2000) in Platinum -Based Drugs in Cancer Therapy (Kelland, L. R., and Farrell, N. P., eds) pp. 37-61, Humana Press Inc., Totowa, NJ
34. Keck, M. V., and Lippard, S. J. (1992) J. Am. Chem. Soc. 114, 3386-3390
35. Brabec, V., Sip, M., and Leng, M. (1993) Biochemistry 32, 11676-11681
36. Teuben, J. M., Bauer, C., Wang, A. H. J., and Reedijk, J. (1999) Biochemistry 38, 12305-12312
37. Imamura, T., Izumi, H., Nagatani, G., Ise, T., Nomoto, M., Iwamoto, Y., and Kohno, K. (2001) J. Biol. Chem. 276, 7534-7540